What Diabetes Trials Are Running Right Now
The landscape of diabetes research in the U.S. has shifted noticeably in recent years. Investigational medications that combine existing drug classes — like the dual GLP-1/GIP agonists and amylin analogues — dominate new recruiting studies. One example actively recruiting across Alabama, California, Florida, Minnesota, New York, Tennessee, Texas, and Virginia examines how well a new once-weekly medication helps adults with type 2 diabetes and excess body weight lose weight while improving glycemic control. Another Phase 3 program enrolling up to 1,600 participants is testing multiple doses of a dual receptor agonist in people with obesity or overweight and type 2 diabetes, with sites spread across Arizona, California, Florida, and beyond.
Trials aren't limited to pharmaceuticals, either. A randomized controlled study in Arkansas delivered healthy meals to food-insecure adults with type 2 diabetes in rural clinics, comparing that intervention against standard diabetes education alone. The premise was straightforward: when transportation is scarce and healthy food options are limited, addressing what lands on the plate matters as much as the prescription pad. Researchers tracked HbA1c, blood pressure, cholesterol, and diet quality scores, and the model reflects a broader push to treat diabetes within the social conditions that shape it.
Who Qualifies and What Participation Looks Like
Eligibility varies widely by study, but a few patterns hold. Most type 2 diabetes trials require an HbA1c between 7 and 10 percent, a diagnosis at least six months old, and stable use of zero to three oral diabetes medications. People currently taking GLP-1 receptor agonists or amylin analogues are typically excluded, since those would interfere with what the study measures. Type 1 diabetes prevention studies, meanwhile, target younger people — sometimes ages 1 to 35 — who carry two or more diabetes-related autoantibodies and meet criteria for early-stage disease.
Expect a screening period that can last several weeks. One trial investigating an investigational cortisol-targeting drug for hard-to-treat type 2 diabetes runs a five-to-nine-week screening phase before participants are randomized to placebo or one of four doses. Treatment phases commonly run 24 to 84 weeks, with follow-up phone calls after the final dose. That's a real time commitment, and one worth weighing against work schedules, travel, and family obligations before you sign.
Randomization deserves honest acknowledgment: you may receive placebo. Most studies are double-blind, meaning neither you nor the study team knows which arm you're in. Some trials offer an open-label extension afterward, but there's no guarantee. If the idea of being on placebo for a year makes you uneasy, ask the study coordinator whether the trial includes a rescue option for participants whose glucose rises above a certain threshold — many do.
What It Costs and What You Get
Compensation is common but rarely spectacular. A Boston Children's Hospital diet study for young adults with type 1 diabetes offers up to $1,300 for time and effort, reimburses parking and local transportation, and provides all meals through a delivery service with no out-of-pocket cost. Iowa Diabetes Research, which runs multiple studies, notes that participants typically receive expert diabetes care worth several hundred dollars per visit and travel stipends for scheduled appointments. Studies routinely cover study-related medications, supplies, and lab work — that part is genuine.
What you won't find is a one-size-fits-all payment schedule. Reimbursement varies by trial length, visit count, and whether the sponsor covers travel. Ask upfront about stipend amounts, how often you'll be reimbursed, and what happens to compensation if you withdraw early. Withdrawal is always allowed — participation is voluntary at every stage — and most sponsors prorate payments based on how long you stayed in the study.
A Closer Look at Trial Types
| Trial Category | Example Study Focus | Typical Duration | What You Get | Considerations |
|---|
| Investigational medication (Phase 2/3) | Once-weekly dual agonist for weight and glucose control | 1–1.5 years | Study drug, monitoring, specialist visits covered | Placebo possible; frequent in-person visits |
| Device or delivery intervention | Home food delivery for rural patients | 12–24 weeks | Meals, diabetes education, supplies | Location-dependent; may require in-person visits |
| Prevention / early-stage (Type 1) | Oral medication to delay onset | 6 months to 2+ years | Free study medication, close monitoring | Strict autoantibody eligibility criteria |
| Behavioral / diet comparison | Very low carbohydrate vs. standard diet | 12 weeks | All food provided, up to ~$1,300 | Randomized to diet group; no choice |
Where to Find Trials Near You
ClinicalTrials.gov remains the most reliable starting point. Filter by condition, state, and recruiting status, and pay attention to the "Last Update Posted" date — stale listings happen. Most study pages list a central contact person with a phone number and email, and many sponsors now operate patient-facing portals. Roche's diabetes trials, for example, route inquiries through a dedicated patient contact form. Novo Nordisk posts a central clinical trials line you can call directly.
Local academic medical centers are another route. University of Colorado Hospital, UT Southwestern in Dallas, and the International Diabetes Center in Minneapolis all host active diabetes trials. If you live near a research hospital, ask your endocrinologist whether they refer patients into studies — they often know which trials are enrolling and can match you to one based on your HbA1c, medication history, and complications profile. Diabetes specialty clinics like Iowa Diabetes Research also maintain their own study pipelines with navigators who help match patients to trials.
Questions to Ask Before You Enroll
Treat the screening visit as an interview in both directions. The study team evaluates you; you should evaluate the study. Practical questions to bring: How many visits are required and where exactly? Who covers travel and parking? Will you coordinate with my regular diabetes doctor, or take over my care during the trial? What happens if my glucose control worsens while I'm on placebo? Is there an open-label extension after the blinded phase ends? Can I see the informed consent document before I commit?
One more thing worth asking: what happens after the trial ends. Some studies transition participants to standard care; others offer continued access to the investigational drug until it's commercially available. Knowing that answer before you enroll prevents disappointment later.
Making the Call
Diabetes trials offer something ordinary care often can't: close monitoring, access to emerging treatments, and specialists who watch your numbers weekly instead of quarterly. For rural patients facing food insecurity, some trials even tackle the grocery problem directly. But they also demand time, patience with randomization, and a willingness to travel to research sites that may be an hour or more from home.
Start by checking the recruiting studies in your state, then talk to your diabetes care team. Between the two, you'll get a realistic picture of what participation means for your particular situation — and whether stepping into a trial is the right next step in your management plan.
研究の知恵